关于推荐2010年中国药学会-赛诺菲安万特青年生物药物奖的通知

中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲-安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,从2009年     

关于推荐2010年中国药学会-赛诺菲安万特青年生物药物奖的通知

中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲-安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,从2009年     

关于推荐2010年中国药学会-赛诺菲安万特青年生物药物奖的通知

中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲-安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,从2009年     

关于推荐2011年中国药学会-赛诺菲安万特青年生物药物奖的通知

中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲。安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,     

关于推荐2011年中国药学会-赛诺菲安万特青年生物药物奖的通知

中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲-安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,从2009年起每年评选一次,每次奖励8名从事生物药物研究的青年学者,奖励金额(含税)为每人20000元人民币,同时颁发获奖证书。     

关于推荐2011年中国药学会-赛诺菲安万特青年生物药物奖的通知

本会各专业委员会,各省、自治区、直辖市、计划单列市及有关副省级城市药学会,各有关单位:中国药学会-赛诺菲安万特青年生物药物奖是中国药学会与赛诺菲-安万特公司共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,从2009年起每年评选一次,每次奖励8名从事生物药物研究的青年学者,奖励金额(含税)为每人20000元人民币,同时颁发获奖证书。现将有关事宜通知如下。     

关于推荐第八届中国药学会-赛诺菲青年生物药物奖候选人的通知

中国药学会-赛诺菲青年生物药物奖是中国药学会与赛诺菲(中国)投资有限公司上海分公司("赛诺菲中国")自2009年起共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。第八届中国药学会-赛诺菲青年生物药物奖面向全国评选奖励8名从事生物药物研究的优秀青年学者。     

中国药学会2011年各奖项申报通知

2011年中国药学会设立了以下奖项：（1）2011年中国药学会科学技术奖;（2）第14届中国药学会一施维雅青年药物化学奖和专项研究资助项目;（3）2011年中国药学会一石药集团青年药剂学奖;（4）2011年中国药学会一赛诺菲安万特青年生物药物奖。详情请登陆中国药学会网站（http：／／www．cpa．org．cn／）首贞,点击进入学术交流栏目查看。     

关于推荐2012年中国药学会-赛诺菲青年生物药物奖的通知

中国药学会-赛诺菲青年生物药物奖是中国药学会与赛诺菲公司2009年共同设立的青年生物药物奖,旨在奖励中国优秀青年生物药物工作者,致力于生物药物新药研究。该奖项面向全国,每年评选一次,每次奖励8名从事生物药物研究的青年学者,奖励金额（含税）为每人20000元人民币,     

关于举办2011年中国药学大会暨第11届中国药师周的通知(第二轮)

由中国药学会主办、绿叶制药集团有限公司等协办的2011年中国药学大会暨第11届中国药师周大会,定于2011年11月5日至6日在山东省烟台市举行。大会将邀请国家及医药卫生科技领域政府部门领导、两院院士等作主会场大会报告,同时进行二十个专业分会场及卫星会场专题报告、论文交流和壁报交流。大会开幕式上颁发2011年中国药学会科学技术奖、中国药学会-赛诺菲安万特青年生物药物奖、     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

Aquatic Insects and Trace Metals: Bioavailability,Bioaccumulation, and Toxicity

Abstract

The uptake of metals from food and water sources by insects is thought to be additive. For a given metal, the proportions taken up from water and food will depend both on the bioavailable concentration of the metal associated with each source and the mechanism and rate by which the metal enters the insect. Attempts to correlate insect trace metal concentrations with the trophic level of insects should be made with a knowledge of the feeding relationships of the individual taxa concerned. Pathways for the uptake of essential metals, such as copper and zinc, exist at the cellular level, and other nonessential metals, such as cadmium, also appear to enter via these routes. Within cells, trace metals can be bound to proteins or stored in granules. The internal distribution of metals among body tissues is very heterogeneous, and distribution patterns tend to be both metal and taxon specific. Trace metals associated with insects can be both bound on the surface of their chitinous exoskeleton and incorporated into body tissues. The quantities of trace meals accumulated by an individual reflect the net balance between the rate of metal influx from both dissolved and particulate sources and the rate of metal efflux from the organism. The toxicity of metals has been demonstrated at all levels of biological organization: cell, tissue, individual, population, and community. Much of the literature pertaining to the toxic effects of metals on aquatic insects is based on laboratory observations and, as such, it is difficult to extrapolate the data to insects in nature. The few experimental studies in nature suggest that trace metal contaminants can affect both the distribution and the abundance of aquatic insects. Insects have a largely unexploited potential as biomonitors of metal contamination in nature. A better understanding of the physico-chemical and biological mechanisms mediating trace metal bioavailability and exchange will facilitate the development of general predictive models relating trace metal concentrations in insects to those in their environment. Such models will facilitate the use of insects as contaminant biomonitors.     

Alzheimer’s disease – current trends in basic and clinical research. Highlights from the 16th ECNP

Advances in the molecular biological knowledge of neuronal nicotinic acetylcholine receptors (nAChRs) have led to a growing interest by the pharmaceutical industry in the development of novel compounds that selectively modulate nAChR function. The ability of (-)-nicotine, an activator of nAChRs, to enhance attentional aspects of cognition in animals and humans, to exert neuroprotective and anxiolytic-like effects, and presumably to mediate the negative correlation between smoking and Alzheimer's (and Parkinson's) Disease, has focused interest on the potential therapeutic utility of modulators of nAChR function for treatment of some of the deficits associated with these progressive, neurodegenerative conditions. Numerous compounds are known which activate nAChRs and which might serve as lead compounds toward the development of such agents. The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favourable side-effect profiles than existing agents. This broader class of agents, collectively called cholinergic channel modulators (ChCMs), is anticipated to encompass compounds which would have more favourable side-effect profiles than existing agents, which generally exhibit low selectivity. This selectivity may be achieved by preferentially activating some subtypes of nAChRs (i.e., Cholinergic Channel Activators, ChCAs) or inhibiting the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs). An overview of the biology of nAChRs and the rationale for the use of ChCMs for the treatment of dementia related to neurodegenerative diseases are presented, followed by a discussion of lead compounds and compounds under consideration for clinical evaluation.     

2-(Acetoxyphenyl)-(Z)-styryl sulfides as cyclooxygenase inhibitors

2-(Acetoxyphenyl)-(Z)-styryl sulfides are described as selective cyclooxygenase-2 (COX-2) inhibitors, useful for treating inflammation and COX-2-mediated disorders including neoplasia. 2-(Acetoxyphenyl)-(Z)-styryl sulfide is claimed to be the most potent COX inhibitor in the series with a COX-2 selectivity ratio of 33. This compound is also claimed to be superior to celecoxib (Celebrex^®, Pfizer) in inhibiting cell growth of colorectal carcinoma cells. In this evaluation, the COX inhibitory activity of this compound is compared to that previously disclosed for diarylheterocycles and 2-(acetoxyphenyl)alkyl sulfides. The validity of the DLD-1 cell line in the growth inhibition studies is questioned based on recent literature reports indicating the lack of COX-2 expression in this cell line.     

Sleep-disordered breathing with chronic opioid use

Chronic opioid use for pain relief or as substitution therapy for illicit drug abuse is prevalent in our societies. In the US, retail distribution of methadone and oxycodone has increased by 824 and 660%, respectively, between 1997 and 2003. μ-Opioids depress respiration and deaths related to illicit and non illicit chronic opioid use are not uncommon. Since 2001 there has been an emerging literature that suggests that chronic opioid use is related to central sleep apnoea of both periodic and non-periodic breathing types, and occurs in ～ 30% of these subjects. The clinical significance of these sleep-related abnormalities are unknown. This review addresses the present knowledge of control of ventilation mechanisms during wakefulness and sleep, the effects of opioids on ventilatory control mechanisms, the sleep-disordered breathing found with chronic opioid use and a discussion regarding the future research directions in this area.     

Drug targets for cognitive enhancement in neuropsychiatric disorders

The investigation of novel drug targets for treating cognitive impairments associated with neurological and psychiatric disorders remains a primary focus of study in central nervous system (CNS) research. Many promising new therapies are progressing through preclinical and clinical development, and offer the potential of improved treatment options for neurodegenerative diseases such as Alzheimer's disease (AD) as well as other disorders that have not been particularly well treated to date like the cognitive impairments associated with schizophrenia (CIAS). Among targets under investigation, cholinergic receptors have received much attention with several nicotinic agonists (α7 and α4β2) actively in clinical trials for the treatment of AD, CIAS and attention deficit hyperactivity disorder (ADHD). Both glutamatergic and serotonergic (5-HT) agonists and antagonists have profound effects on neurotransmission and improve cognitive function in preclinical experiments with animals; some of these compounds are now in proof-of-concept studies in humans. Several histamine H3 receptor antagonists are in clinical development not only for cognitive enhancement, but also for the treatment of narcolepsy and cognitive deficits due to sleep deprivation because of their expression in brain sleep centers. Compounds that dampen inhibitory tone (e.g., GABA_A α5 inverse agonists) or elevate excitatory tone (e.g., glycine transporter inhibitors) offer novel approaches for treating diseases such as schizophrenia, AD and Down syndrome. In addition to cell surface receptors, intracellular drug targets such as the phosphodiesterases (PDEs) are known to impact signaling pathways that affect long-term memory formation and working memory. Overall, there is a genuine need to treat cognitive deficits associated with many neuropsychiatric conditions as well as an increasingly aging population.